Biotec Pharmacon ASA Solidifies Efforts In Cancer Adjuvant Therapy
Biotec Pharmacon ASA strengthens its proprietary patent coverage for the combination of monoclonal antibodies and yeast beta glucan for treatment of different types of cancer
TROMSØ, NORWAY, February 16, 2012 – Biotec Pharmacon ASA (OSE: BIOTEC) has been issued two patents that cover the combination of monoclonal antibodies and yeast beta glucan for treatment of a large variety of cancers by the Japanese and the Indian Patent Offices.
Biotec Pharmacon has developed this concept together with Memorial Sloan-Kettering Cancer Center (MSKCC). Biotec Pharmacon and MSKCC are joint owners of this technology and the company has an exclusive license on MSKCC’s rights to these patents.
Adding these two patents to the already large portfolio of existing patents, Biotec Pharmacon has now established a strong proprietary position on this field with approved patents in the USA, Canada, Japan, India, Australia and Mexico. Several other international patent applications are still pending in major jurisdictions.
"These latest two patents will undoubtedly position Biotec Pharmacon in a strong situation also in the field of glucan adjuvant cancer therapy." said Svein Lien, CEO, Biotec Pharmacon ASA. "We are looking forward to receive further approvals in other countries which will then give us an almost global protection." he says.
The patents cover a pharmaceutical combination for the treatment of cancer expressing certain antigens comprising as active ingredients a complement-activating antibody capable of binding to certain antigens, and a β-glucan defined by its structure and/or its origin.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information:
CEO Svein W. F. Lien - +47 92289323
CSO Rolf Engstad - +47 95941542
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The wholly owned Biotec BetaGlucans AS focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in wound treatment, cancer and gastroenterology. The company’s technology is protected by a large patent portfolio covering amongst others applications of yeast beta glucans as adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes AS aspires to become a leading supplier of novel enzymes for diagnostics and genetic research. More information on www.biotec.no.
Statement under the Private Securities Litigation Reform Act:
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, product acceptance, the ability to continually obtained increased orders of its products, the ability to meet installation goals, economic, competitive, governmental impacts, whether pending patents will be granted or defendable, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, as well as technological and/or other factors.
Tags: